610 related articles for article (PubMed ID: 24798740)
21. Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns.
Rivera M; Ricarte-Filho J; Knauf J; Shaha A; Tuttle M; Fagin JA; Ghossein RA
Mod Pathol; 2010 Sep; 23(9):1191-200. PubMed ID: 20526288
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic alterations in papillary thyroid cancers of young patients.
Sassolas G; Hafdi-Nejjari Z; Ferraro A; Decaussin-Petrucci M; Rousset B; Borson-Chazot F; Borbone E; Berger N; Fusco A
Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560
[TBL] [Abstract][Full Text] [Related]
23. Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population.
Brzeziańska E; Pastuszak-Lewandoska D; Wojciechowska K; Migdalska-Sek M; Cyniak-Magierska A; Nawrot E; Lewiński A
Neuro Endocrinol Lett; 2007 Aug; 28(4):351-9. PubMed ID: 17693984
[TBL] [Abstract][Full Text] [Related]
24. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
25. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF
Lee SE; Hwang TS; Choi YL; Kim WY; Han HS; Lim SD; Kim WS; Yoo YB; Kim SK
Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988
[TBL] [Abstract][Full Text] [Related]
26. [BRAF initiating mutations in the papillary thyroid carcinoma].
Rusinek D; Gubała E
Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
[TBL] [Abstract][Full Text] [Related]
27. [The correlation between BRAF mutations, RET/PTC rearrangements and platelet-derived growth factor B expression in papillary thyroid carcinomas].
Wang P; Wang YG; Zhao WJ; Fu YD; Wang L; Wang F; Zhao SH
Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):987-91. PubMed ID: 23327964
[TBL] [Abstract][Full Text] [Related]
28. Application of BRAF, NRAS, KRAS mutations as markers for the detection of papillary thyroid cancer from FNAB specimens by pyrosequencing analysis.
Park SJ; Sun JY; Hong K; Kwak JY; Kim EK; Chung WY; Choi JR
Clin Chem Lab Med; 2013 Aug; 51(8):1673-80. PubMed ID: 23585181
[TBL] [Abstract][Full Text] [Related]
29. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
[TBL] [Abstract][Full Text] [Related]
30. [Pathogenesis of differentiated thyroid cancer (papillary and follicular)].
Maciel RM; Kimura ET; Cerutti JM
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):691-700. PubMed ID: 16444351
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
32. Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions.
Mostoufi-Moab S; Labourier E; Sullivan L; LiVolsi V; Li Y; Xiao R; Beaudenon-Huibregtse S; Kazahaya K; Adzick NS; Baloch Z; Bauer AJ
Thyroid; 2018 Jan; 28(1):60-67. PubMed ID: 29108474
[TBL] [Abstract][Full Text] [Related]
33. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma.
Henderson YC; Shellenberger TD; Williams MD; El-Naggar AK; Fredrick MJ; Cieply KM; Clayman GL
Clin Cancer Res; 2009 Jan; 15(2):485-91. PubMed ID: 19147753
[TBL] [Abstract][Full Text] [Related]
34. Molecular and histopathologic characteristics of multifocal papillary thyroid carcinoma.
Bansal M; Gandhi M; Ferris RL; Nikiforova MN; Yip L; Carty SE; Nikiforov YE
Am J Surg Pathol; 2013 Oct; 37(10):1586-91. PubMed ID: 23797723
[TBL] [Abstract][Full Text] [Related]
35. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis.
Musholt TJ; Staubitz JI; Antonio Cámara RJ; Musholt PB; Humberg D; Springer E; Schad A
Eur J Surg Oncol; 2019 Jun; 45(6):1018-1024. PubMed ID: 30472213
[TBL] [Abstract][Full Text] [Related]
36. BRAF in papillary thyroid carcinoma of ovary (struma ovarii).
Schmidt J; Derr V; Heinrich MC; Crum CP; Fletcher JA; Corless CL; Nosé V
Am J Surg Pathol; 2007 Sep; 31(9):1337-43. PubMed ID: 17721188
[TBL] [Abstract][Full Text] [Related]
37. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
[TBL] [Abstract][Full Text] [Related]
38. Lack of association between BRAF V600E mutation and mitogen-activated protein kinase activation in papillary thyroid carcinoma.
Zuo H; Nakamura Y; Yasuoka H; Zhang P; Nakamura M; Mori I; Miyauchi A; Kakudo K
Pathol Int; 2007 Jan; 57(1):12-20. PubMed ID: 17199737
[TBL] [Abstract][Full Text] [Related]
39. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
Henderson YC; Fredrick MJ; Clayman GL
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
[TBL] [Abstract][Full Text] [Related]
40. [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene].
Vasil'ev EV; Rumiantsev PO; Saenko VA; Il'in AA; Poliakova EIu; Nemtsova MV; Zaletaev DV
Mol Biol (Mosk); 2004; 38(4):642-53. PubMed ID: 15456136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]